#USA #New York #Securities Fraud #Pomerantz LLP #AQST

Pomerantz Law Firm Investigates Claims on Behalf of Investors in Aquestive Therapeutics, Inc.

Pomerantz LLP, a leading name in legal advocacy, has begun an investigation into claims from investors regarding Aquestive Therapeutics, Inc. (NASDAQ: AQST). The firm is focusing on potential securities fraud and other unlawful business practices that may have impacted the financial integrity of the company and its shareholders.

Background of the Investigation

The inquiry follows a critical announcement made by Aquestive's President and CEO on January 9, 2026. The FDA reported deficiencies related to the company’s New Drug Application (NDA) for Anaphylm, which hindered further discussions on labeling and post-marketing commitments. Notably, the announcement did not detail the specific deficiencies identified by the FDA, raising concerns among investors about the company's operational and regulatory standing. Following this news, Aquestive's stock witnessed a dramatic decline, plummeting by $2.30 or 37.04%, closing at $3.91 per share on the day of the announcement.

Pomerantz’s Role in Investor Protection

Pomerantz LLP, established for over 85 years, holds a strong reputation for standing up for victims of securities fraud and corporate misconduct. The firm's founder, Abraham L. Pomerantz, is recognized as a pioneer in the field of securities class actions. His legacy continues as Pomerantz fights for the rights of shareholders, aiming to achieve justice and recover damages for those affected by potential corporate malfeasance.

With offices located in prominent cities, including New York, Chicago, Los Angeles, London, and Paris, Pomerantz has successfully handled numerous cases that have resulted in multimillion-dollar settlements, emphasizing their commitment to defending investors' interests.

Implications for Aquestive Investors

Investors who may have suffered losses due to the stock’s fluctuation can contact Danielle Peyton through the firm’s dedicated channels. Pomerantz encourages affected investors to step forward to discuss potential involvement in class action lawsuits that might emerge from this situation. The firm's commitment to transparency and support may be crucial for investors seeking recourse.

Conclusion

As regulatory evaluations continue to unfold for Aquestive Therapeutics, investors remain on high alert. With Pomerantz LLP leading the investigation, those who believe they have claims are urged to seek the help of a law firm that specializes in securities litigation and investor protection. The allegations of fraud, if proven, could significantly impact the future of both the company and its shareholders.

For those interested in learning more or considering participation in the class action, please reach out to Danielle Peyton at Pomerantz LLP at [email protected] or call 646-581-9980, ext. 7980, for further assistance.

This article serves as an alert to investors regarding potential corporate misconduct and does not constitute legal advice.